Form 4: Oncology Institute Director Anne McGeorge Acquires 56,000 Restricted Stock Units

Director Anne McGeorge of Oncology Institute, Inc. acquired 56,000 restricted stock units, which will vest at the 2025 annual shareholder meeting.

Summary

• Anne McGeorge, a director at Oncology Institute, Inc., acquired 56,000 restricted stock units on November 22, 2024.
• These restricted stock units will vest fully on the date of TOI, Inc.'s 2025 annual shareholder meeting, contingent on her continued service with the company.
• Following this transaction, Ms. McGeorge's total direct holdings include 183,346 common stock shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of restricted stock units being granted to a director, which is generally viewed as a positive sign of alignment between management and shareholders. It is not a major event but is a normal part of corporate governance.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.
• The vesting of the units is tied to continued service, aligning the director's interests with the company's long-term success.

Future Outlook

The restricted stock units will vest at the 2025 annual shareholder meeting, subject to continued service.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The acquisition of restricted stock units by directors is a common practice in publicly traded companies as part of their compensation and incentive programs.
• Similar filings are regularly made by directors and officers of other companies in the healthcare and biotechnology sectors.

Stakeholder Impact

• The acquisition of restricted stock units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Next Steps

• The restricted stock units will vest at the 2025 annual shareholder meeting, contingent on continued service.

Key Dates

Keywords

restricted stock units, director, insider trading, beneficial ownership, Oncology Institute, TOI, equity